Fri, Jul 25, 2014, 5:14 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

OncoGenex Pharmaceuticals, Inc. Message Board

  • Posting here has become so frustrating (Yahoo's infernal spam filter swallowed several previous attempts.) In any event, following is Adam Feuerstein's synopsis on 011. AF is a biotech journalist (not an analyst.) Although he is sometimes accused of bashing, I've found most of his articles to be substantive rather than subjective. I've taken a 50% position in OGXI, and intend to buy the rest (double down) if 011 disappoints. Of course, I'd be very happy with what I have if OGXI were to surprise to the upside based on 011 news. FWIW, AF on 011:

    OGX-011 is designed to inhibit a protein known as clusterin that plays a role in cell survival. By knocking out clusterin in tumors, OGX-011 makes cancer cells more vulnerable to chemotherapy and other tumor-killing drugs.

    OGX-011 is being developed in prostate cancer as an add-on to Taxotere, the chemotherapy drug considered standard of care for patients with advanced disease. In a phase II study enrolling 82 patients and presented in 2009, the median overall survival for the men treated with OGX-011 plus Taxotere was 23.8 months compared to 16.9 months for men treated with Taxotere alone -- an improvement in survival of 6.9 months favoring OGX-011. Expressed another way, treatment with OGX-011 reduced the risk of death by 39% compared to treatment with Taxotere alone.

    While this result was not statistically significant, the strong trend favoring a survival benefit for OGX-011 was compelling because the data came from a randomized, controlled trial.

    Doubts cast upon the reliability of the phase II data centered mainly around the fact that OGX-011's survival benefit came despite the drug having little or no measurable effect on tumor progression compared to Taxotere alone. Fifty-eight percent of men treated in the OGX-011 arm reported a PSA response compared to 54% of men in the Taxotere-alone arm. PSA is a commonly used biomarker for prostate tumor growth. Progression-free survival was 7.3 months for the OGX-011-treated men compared to 6.1 months for the men treated with Taxotere alone. The median number of treatment cycles administered was also greater in the OGX-011 arm (nine cycles) compared to seven cycles for men in the Taxotere arm of the study.

 
OGXI
3.15-0.03(-0.94%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.